WO2010087964A3 - Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés - Google Patents

Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés Download PDF

Info

Publication number
WO2010087964A3
WO2010087964A3 PCT/US2010/000236 US2010000236W WO2010087964A3 WO 2010087964 A3 WO2010087964 A3 WO 2010087964A3 US 2010000236 W US2010000236 W US 2010000236W WO 2010087964 A3 WO2010087964 A3 WO 2010087964A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
acne
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/000236
Other languages
English (en)
Other versions
WO2010087964A2 (fr
Inventor
Joyce A. Sutcliffe
Susan M. Ciotti
James R. Baker, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanobio Corp
Original Assignee
Nanobio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobio Corp filed Critical Nanobio Corp
Priority to EP10703377A priority Critical patent/EP2391342A2/fr
Priority to CA2750233A priority patent/CA2750233A1/fr
Publication of WO2010087964A2 publication Critical patent/WO2010087964A2/fr
Publication of WO2010087964A3 publication Critical patent/WO2010087964A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/21—Emulsions characterized by droplet sizes below 1 micron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des procédés permettant de traiter et de prévenir l'acné ou l'infection à P. acnes chez un sujet comprenant l'administration topique au sujet en ayant besoin d'une nanoémulsion anti-acnéique.
PCT/US2010/000236 2009-01-28 2010-01-28 Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés Ceased WO2010087964A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10703377A EP2391342A2 (fr) 2009-01-28 2010-01-28 Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés
CA2750233A CA2750233A1 (fr) 2009-01-28 2010-01-28 Composition pour le traitement et la prevention de l'acne, procedes de fabrication des compositions, et procedes d'utilisation associes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14796009P 2009-01-28 2009-01-28
US61/147,960 2009-01-28

Publications (2)

Publication Number Publication Date
WO2010087964A2 WO2010087964A2 (fr) 2010-08-05
WO2010087964A3 true WO2010087964A3 (fr) 2011-06-16

Family

ID=42077664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000236 Ceased WO2010087964A2 (fr) 2009-01-28 2010-01-28 Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés

Country Status (4)

Country Link
US (1) US20100226983A1 (fr)
EP (1) EP2391342A2 (fr)
CA (1) CA2750233A1 (fr)
WO (1) WO2010087964A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
SG10201607909WA (en) 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (fr) 2006-12-01 2008-06-12 Anterios, Inc. Nanoparticules à entités amphiphiles
WO2008151022A2 (fr) 2007-05-31 2008-12-11 Anterios, Inc. Nanoparticules d'acide nucléique et leurs utilisations
US9814422B2 (en) 2007-08-06 2017-11-14 The Regents Of The University Of California Compositions for solubilizing cells and/or tissue
US20110082216A1 (en) * 2009-10-02 2011-04-07 Wu Jeffrey M Benzoyl peroxide composition for treating skin
CN103533926A (zh) * 2011-01-24 2014-01-22 安特里奥公司 空纳米颗粒组合物及其用于治疗皮肤病学病症的用途
CN102166270A (zh) * 2011-04-06 2011-08-31 西北农林科技大学 一种水包油型陈皮油纳米乳及其制备方法
SE1300709A1 (sv) * 2013-11-14 2015-05-15 Lipidor Ab Komposition och metod för topikal behandling
US10206996B2 (en) 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
JP6460792B2 (ja) 2011-09-09 2019-01-30 ナノバイオ コーポレーション ナノエマルション呼吸器合胞体ウイルス（ｒｓｖ）サブユニットワクチン
EP2763668A4 (fr) * 2011-10-05 2015-04-15 Douglas Pharmaceuticals Ltd Procédés pharmaceutiques et compositions topiques contenant de l'acitrétine
CN102526163A (zh) * 2011-12-27 2012-07-04 浙江景岳堂药业有限公司 一种用于风痛灵中乳香和没药的提取方法
US20130224268A1 (en) * 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
MX369625B (es) * 2012-05-16 2019-11-14 Univ California Composiciones para solubilizar celulas y/o tejido.
US20130337095A1 (en) * 2012-06-18 2013-12-19 Waikatolink Limited Antimicrobial composition and its method of use
GB2503235A (en) * 2012-06-20 2013-12-25 Quest Vitamins Ltd Synergistic composition for minimising bacterial infection in animals
EP2968136B1 (fr) 2013-03-13 2017-12-13 Santalis Healthcare Corporation Formulations de crème stabilisées comprenant de l'essence de santal
GB201313803D0 (en) * 2013-08-01 2013-09-18 Omex Agriculture Ltd Fungicidal composition and method
DE102014102400A1 (de) * 2014-02-25 2015-08-27 Reinhard Caliebe Topische kosmetische oder pharmazeutische Zusammensetzung
CN104738032B (zh) * 2015-02-12 2017-03-08 河南科技学院 一种氯甲酚纳米乳消毒剂及其制备方法
US12290599B2 (en) 2015-06-19 2025-05-06 Global Health Solutions Llc Oil-based wound care compositions and methods
WO2016204959A1 (fr) * 2015-06-19 2016-12-22 Global Health Solutions, Inc. Systèmes d'administration à base de vaseline pour des principes actifs
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
EP3328359A4 (fr) * 2015-07-31 2019-03-27 NanoBio Corporation Méthodes de traitement de l'acné à l'aide de compositions en nanoémulsion
EP3359176A4 (fr) 2015-10-07 2019-06-12 Santalis Pharmaceuticals Inc. Essence de santal et ses utilisations liées à la mucosite buccale
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
CN110167516B (zh) 2017-01-31 2022-08-30 金伯利-克拉克环球有限公司 包含苯甲酸酯的抗细菌组合物及利用该组合物抑制细菌生长的方法
US11241385B2 (en) * 2017-09-26 2022-02-08 Johnson & Johnson Consumer Inc. Topical composition and method for treating and preventing atopic dermatitis and infections related to bacteria biofilm
EP3880173A1 (fr) 2018-11-15 2021-09-22 Bluewillow Biologics, Inc. Compositions de nano-émulsion présentant une perméabilité améliorée
US11369578B2 (en) 2018-11-15 2022-06-28 Bluewillow Biologics, Inc. Persistent topical antimicrobial compositions and methods of using the same
CN109541118A (zh) * 2018-12-27 2019-03-29 江苏艾兰得营养品有限公司 一种能快速直观鉴别杜松子提取物的方法
WO2021022045A1 (fr) 2019-07-31 2021-02-04 Ecolab Usa Inc. Compositions de détartrage sans équipement de protection individuelle
WO2021087051A1 (fr) * 2019-10-30 2021-05-06 Ps Therapy Ltd. Compositions topiques et leurs procédés d'utilisation
EP4143135A4 (fr) * 2020-04-29 2024-06-05 Kao Corporation Compositions autobronzantes contenant un sulfonate d'alkyle et méthodes associées
CN114099440B (zh) * 2021-12-08 2023-06-13 中国药科大学 一种装载疏水性抗氧化药物的传递体局部药物递送系统
US20250375363A1 (en) * 2022-06-29 2025-12-11 Conopco, Inc., D/B/A Unilever Anti-acne composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549901A (en) * 1994-05-20 1996-08-27 Novavax, Inc. Antimicrobial oil-in-water emulsions
US20020119207A1 (en) * 1999-04-28 2002-08-29 The Regent Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
WO2009158687A1 (fr) * 2008-06-26 2009-12-30 Anterios, Inc. Administration dermique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5103497A (en) * 1989-11-14 1992-04-07 Hicks John W Flying spot endoscope
AU641466B2 (en) * 1990-01-19 1993-09-23 Shiseido Company Ltd. Dermatologic preparation
JP2937667B2 (ja) * 1992-11-19 1999-08-23 高砂香料工業株式会社 尋常性ざ瘡用皮膚外用剤
US6015832A (en) * 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) * 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
GEP20043286B (en) 2000-02-02 2004-07-26 Warner Lambert Co Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders
WO2004030608A2 (fr) * 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Vaccins sous forme de nanoemulsion
WO2005030172A1 (fr) 2003-09-24 2005-04-07 The Regents Of The University And Methods Compositions antimicrobiennes en nanoemulsion et methodes associees
CA2604392A1 (fr) * 2005-04-11 2006-10-19 Nanobio Corporation Halogenures d'ammonium quaternaires pour le traitement de pathologies infectieuses
JP2009504805A (ja) * 2005-08-09 2009-02-05 ナノバイオ コーポレーション 抗炎症活性を有するナノエマルジョン組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549901A (en) * 1994-05-20 1996-08-27 Novavax, Inc. Antimicrobial oil-in-water emulsions
US20020119207A1 (en) * 1999-04-28 2002-08-29 The Regent Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
WO2009158687A1 (fr) * 2008-06-26 2009-12-30 Anterios, Inc. Administration dermique

Also Published As

Publication number Publication date
CA2750233A1 (fr) 2010-08-05
WO2010087964A2 (fr) 2010-08-05
EP2391342A2 (fr) 2011-12-07
US20100226983A1 (en) 2010-09-09

Similar Documents

Publication Publication Date Title
WO2010087964A3 (fr) Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2012092336A3 (fr) Profilage moléculaire pour le cancer
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2014018596A3 (fr) Alpha (1,2) fucosyltransférases appropriées pour une utilisation dans la production d'oligosaccharides fucosylés
WO2012088266A3 (fr) Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
WO2009155513A3 (fr) Immunoglobulines présentant une agrégation réduite
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
WO2012170807A3 (fr) Molécules de liaison anti-psl de pseudomonas et leurs utilisations
WO2009039337A3 (fr) Inhibition de l'angiogenèse
HK1210953A1 (en) Methods for treatment of atherosclerosis
WO2010097788A3 (fr) Agents thérapeutiques de visfatine pour traiter l'acné et d'autres conditions
WO2012012278A3 (fr) Compositions et procédés pour le traitement de troubles pathologiques associés à gpr35 et/ou au complexe gpr35-herg
WO2010088450A3 (fr) Procédés de traitement de maladies associées à la modulation de serca
UA107687C2 (ru) Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен.
WO2010032011A3 (fr) Thérapie antifongique
WO2011042902A3 (fr) Microcapsules comprenant du peroxyde de benzoyle et compositions topiques comprenant celles-ci
WO2009090394A3 (fr) Composition pour traiter un trouble de la peau
HK1223632A1 (zh) 靶向的酶化合物及其用途
WO2012024399A3 (fr) Compositions comprenant de la paulownine et/ou des extraits de paulownia et utilisations de celles-ci
WO2010021750A3 (fr) Procédés et compositions pour l'administration de 3-halopyruvate et de composés associés pour le traitement du cancer
WO2009155070A3 (fr) Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques
WO2012078586A3 (fr) Composition pharmaceutique comprenant un sharn nanog, et procédé d'utilisation dudit sharn nanog dans le traitement du cancer
WO2013000895A9 (fr) Dha et epa pour la réduction du stress oxydatif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10703377

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2750233

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010703377

Country of ref document: EP